Mondaq News Alerts (registration) (3) repaglinide was known as an insulin secretagogue having a similar mechanism of action to the sulfonylurea class of secretagogues. The Federal Circuit found no error in the district court's analysis: It is reasonable that an artisan seeking to ...
Healio The HR for rosiglitazone vs. metformin/ sulfonylurea for the endpoint of CV death/MI/stroke was 0.95 (95% CI, 0.78-1.17) vs. 0.93 (95% CI, 0.74-1.15) for the original RECORD results. Treatment comparisons for MI (HR=1.13; 95% CI, 0.8-1.59) and mortality ...
Medscape The thiazolidinedione drug class, which includes rosiglitazone (Avandia, GlaxoSmithKline) as well as pioglitazone, has never been far from controversy. Rosiglitazone was suspended by the European Union in 2010 and its use severely restricted in the ... and more »
FierceBiotech When Onglyza was used in combination with a sulfonylurea or with insulin (two medications known to cause hypoglycemia), the incidence of confirmed hypoglycemia was increased over that of placebo used in combination with a sulfonylurea or with insulin. and more »
PR Newswire (press release) RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE:...
PR Newswire (press release) RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE:...
Toronto NewsFIX Data was gathered from people on one of three medications for type 2 diabetes – thiazolidinedione, sulfonylurea or metformin. They looked at whether a person had refilled their prescription as a guide to medication adherence. The African American ...
Diabetes In Control ... participated in four separate randomized, placebo-controlled, phase III trials in which empagliflozin at 10 or 25 mg/day was given as monotherapy or as an add-on to either metformin, metformin plus a sulfonylurea , or pioglitazone with or without ...
Family Practice News Digital Network ... participated in four separate randomized, placebo-controlled, phase III trials in which empagliflozin at 10 or 25 mg/day was given as monotherapy or as an add-on to either metformin, metformin plus a sulfonylurea , or pioglitazone with or without ... and more »
Family Practice News Digital Network ... participated in four separate randomized, placebo-controlled, phase III trials in which empagliflozin at 10 or 25 mg/day was given as monotherapy or as an add-on to either metformin, metformin plus a sulfonylurea , or pioglitazone with or without ... and more »
